NEXT GENERATION GENE THERAPEUTICS
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international inf... luence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.
NEXT GENERATION GENE THERAPEUTICS
Industry:
Genetics Health Care Medical Therapeutics
Founded:
2020-03-01
Address:
Suzhou, Jiangsu, China
Country:
China
Status:
Active
Total Funding:
30 M USD
Investors List
Kington Capital
Kington Capital investment in Series A - Next Generation Gene Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series A - Next Generation Gene Therapeutics
BioVenture
BioVenture investment in Series A - Next Generation Gene Therapeutics
WeDo Capital Management
WeDo Capital Management investment in Series A - Next Generation Gene Therapeutics
More informations about "Next Generation Gene Therapeutics"
Next Generation Gene Therapeutics - Crunchbase
Next Generation Gene Therapeutics is a healthcare company that engages in โฆ See details»
Next Generation Gene Therapeutics - Products, Competitors, โฆ
Next Generation Gene Therapeutics is a gene therapy drug research and development company that focuses on the early development of gene therapy projects, preparation and production โฆ See details»
About Us - Next Generation Gene Therapeutics
NGGT Inc. was established in March 2020 to develop gene therapies to treat retinal, metabolic, and neurodegenerative diseases. Our team is composed of โฆ See details»
Next Generation Gene Therapeutics Secures $40 Million in Series B ...
Jul 12, 2023 Founded in 2020, Next Generation Gene Therapeutics has made significant strides in advancing its pipeline. The companyโs lead pipeline candidate, NGGT001, is a gene therapy โฆ See details»
Home - 5th Next Generation Gene Therapy Vectors 2025
2024 saw huge investments in gene therapy vectors. Following a $1.1 billion acquisition of Kate Therapeutics by Novartis and a collaboration between โฆ See details»
Next Generation Gene Therapeutics - Funding, Financials, โฆ
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jul 11, 2023: Series B - Next โฆ See details»
Our approach to gene therapy | AstraZeneca
Our strategies in gene therapy are two-fold; we leverage CRISPR gene editing techniques to repair broken genes and use adeno-associated viruses (AAV) to โฆ See details»
้ฆ้กต - Next Generation Gene Therapeutics
ๅบๅ ๆฒป็. ๅบๅ ็ๆณๅผๅไบๅปๅญฆ็ๆฐ็บชๅ ๏ผไธบ็ฝ่ง็ ๅๆ ขๆง็ ๆไพไบๅ้ฉๆง็ๆฒป็ๆนๆณใๅฎๆๅฏ่ฝ่ฎฉๆฃ่ ๆ่ฑๆ็ปญๆ่ฏๅ้ข็นไฝ้ข็ๅฐๆฐ๏ผ่ฟไธๆญฃๅธธใๅฅๅบท็็ โฆ See details»
Science & Technology - Next Generation Gene โฆ
Gene therapy represents a groundbreaking approach in the field of medical science, offering potential cures and transformative treatments for a variety of โฆ See details»
NEXT GENERATION GENE THERAPEUTICS (HYBRID โฆ
ABOUT CONFERENCE. Scientific Crew welcomes all the industry leaders, researchers, consultants, and students to its first edition of Next Generation โฆ See details»
News Release - Next Generation Gene Therapeutics
Nov 11, 2024 Next Generation Gene Therapeutics (NGGT) Announces Positive New Data on NGGT002 for the Treatment of Phenylketonuria (PKU) NGGT Inc., (โNext Generation Gene โฆ See details»
Gene Therapy: The Next-Generation Therapeutics and Their
Jun 22, 2022 Recent developments such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated gene editing and its use in vivo have been described here โฆ See details»
Next Generation Gene Therapeutics (NGGT) Announces โฆ
Jan 14, 2025 NGGT Inc., ("Next Generation Gene Therapeutics" or "NGGT" or the "Company"), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation โฆ See details»
Next Generation Gene pioneers gene therapy approach with China โฆ
Nov 11, 2024 Gene therapy faces complexities in delivering treatments due to persistent safety concerns and daunting immune responses, but Next Generation Gene Therapeutics Inc. has โฆ See details»
NGGT Progresses First US Gene Therapy Trials For Rare Conditions โฆ
May 17, 2024 Next Generation Gene Therapeutics is fast-tracking clinical trials in the US for its gene therapy candidates for Bietti's crystalline dystrophy and classic phenylketonuria, โฆ See details»
Next Generation Gene Therapeutics - VentureRadar
Next Generation Gene Therapeutics is a healthcare company specializing in the research and development of gene therapy. Utilizing its proprietary "one target and two bullets" technology, โฆ See details»
Next Generation Gene Therapeutics - Updates, News, Events
Jan 14, 2025 Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. New. Resources. Advanced Search. Start Free โฆ See details»
Biogen Is Trying To Outdo Itself With A Next-Generation Spinraza ...
9 hours ago Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug. 6/23/2025 Exelixis stock surged Monday after the company said its next-generation cancer drug showed โฆ See details»
Advancing gene-editing platforms to improve the viability of rare ...
1 day ago Rare-disease therapeutics face viability challenges due to small patient populations and drug-development and regulatory frameworks that were not developed to address rapidly โฆ See details»
In vivo CAR T cell generation to treat cancer and autoimmune
6 days ago In order for this technology to be used broadly in therapeutics with an acceptable safety profile, we sought to develop a tLNP specifically designed for in vivo mRNA delivery to โฆ See details»